A clinical observational study of dinutuximab beta as first-line maintenance treatment for patients with high-risk neuroblastoma in China

Abstract Background High-risk neuroblastoma (HR-NB) is associated with high metastatic and relapse rates that require intensive multimodal treatment. We evaluated the efficacy and safety of dinutuximab beta as first-line maintenance immunotherapy in pediatric patients with HR-NB in real-world clinic...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Xuedi Yu, Suyi Kang, Junjie Ge, Jingfu Wang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-03-01
Colecção:	BMC Pediatrics
Assuntos:	High-risk neuroblastoma Dinutuximab beta GD2-antibody immunotherapy GM-CSF First-line maintenance Chemotherapy
Acesso em linha:	https://doi.org/10.1186/s12887-025-05568-x
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!